Abstract:Background: ASTRIS is a single-arm, open-label, international multi-center real-world study to evaluate the efficacy and safety of osimertinib. The medium-term analysis data of the Chinese subgroup was reported here. Methods: Advanced or metastatic non-small cell lung cancer (NSCLC) patients treated with Epidermal growth factor receptor-Tyrosine kinase inhibitors (EGFR-TKIs) previously and harboring EGFR T790M mutations were enrolled. The primary endpoint was overall survival (OS), second endpoints were objective response rate (ORR) and progressive-free survival (PFS) evaluated by investigators, time to discontinuation and safety. Results: The protocol planned data cut-off on Oct 20th, 2017. 1350 Chinese patients were enrolled. The median follow-up time was 6.8 months (ranged from 0 to 12 months). EGFR T790M mutation was confirmed by tissue testing (n = 783, cobas® EGFR Mutation Test V1) or plasma testing (n = 567; cobas® EGFR Mutation Test V2 n = 493, others n = 74). Overall ORR is 53.5% (704/1317, 95% CI 50.7-56.2). In patients with EGFR T790M mutation confirmed by tissue (n = 772), the ORR and disease control rate were 57.8% (95% CI, 54.2-61.3) and 97.4%; in patients with EGFR T790M mutation confirmed by plasma (n = 545), the ORR and DCR were 47.3% (95% CI, 43.1-51.6) and 93.7%. OS and PFS were immature, with maturities of 11.9% and 29.9% respectively. 223 (16.5%) patients reported at least one adverse event (AE). serious adverse events were reported in 167 (12.4%) patients, which caused 47 (3.5%) patients to discontinuTable512P Clinical characteristics of the patients at baselineOsimertinib (n=1350)Age-yrMedian60Range29-87Sex-NO. (%)Male545 (40.4%)Female805 (59.6%)Brain metastasis(including LM metastasis) -NO.(%)312 (23.1%)WHO performance status-NO.(%)0 (Normal Activity)270 (20%)1 (Restricted Activity)970 (71.9%)2 (In Bed Less Than or Equal to 50% of the Time)110 (8.1%)Previous EGFR-TKI- NO.(%)Gefitinib722 (53.5%)Icotinib370 (27.4%)Erlotinib283 (21.0%)Others34 (2.5%)Any previous chemotherapy-NO. (%)592 (43.9%)First line437 (32.3%)Second line237 (17.6%)Third line100 (7.4%)>Third line40 (3.0%) Open table in a new tab e the treatment. Conclusions: This interim analysis results demonstrated that osimertinib is effective and well-tolerated in advanced or metastatic NSCLC patients who have EGFR T790M mutation after treatment with EGFR-TKI in the real-world setting of China. Clinical trial identification: NCT02474355. Legal entity responsible for the study: AstraZeneca. Funding: AstraZeneca. Disclosure: Q. Zhou, H. Zhang, L. Jiang, Y. Shi, Y. Chen, J. Yu, Y. He, Y. Hu, Z-A. Liang, Y. Pan, W. Zhuo, Y. Song, G. Wu, G. Chen, Y. Lu, Y. Cheng, S. Lu, J. Wang, Y.L. Wu: This research was funded by AstraZeneca. C. Zhou: Participant in the AURA 17 study.

Efficacy and safety of 40 mg osimertinib administered every other day for non‐small cell lung cancer harboring an epidermal growth factor receptor mutation: A single‐center retrospective cohort study

Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer

Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer

Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer

A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

Analysis of the Clinical Effect of Osimertinib on 90 Cases with Advanced Lung Adenocarcinoma

Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study.

Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older (‘MONEY’ trial)

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

Osimertinib in Patients With Treatment-Naive EGFR -Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status

Osimertinib in Advanced or Metastatic Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation after Treatment with EGFR-TKI: Interim Analysis of China Cohort from the Single-Arm, Open-Label, International, Multi-Center Real-World ASTRIS Study

Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation‐Positive Advanced Non–Small‐Cell Lung Cancer: A Meta‐Analysis

A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study

Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).

Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer